Angina instável

Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-826.Texto completo  Resumo

Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.Texto completo  Resumo

Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Nov 30;78(22):e187-285.Texto completo  Resumo

Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e18-114.Texto completo  Resumo

1. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-826.Texto completo  Resumo

2. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139-228.Texto completo  Resumo

3. Culić V, Eterović D, Mirić D, et al. Symptom presentation of acute myocardial infarction: influence of sex, age, and risk factors. Am Heart J. 2002 Dec;144(6):1012-7. Resumo

4. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021 Nov 30;144(22):e368-454.Texto completo  Resumo

5. World Health Organization. Cardiovascular diseases (CVDs). Jun 2021 [internet publication].Texto completo

6. Timmis A, Vardas P, Townsend N, et al. European Society of Cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022 Feb 22;43(8):716-99.Texto completo  Resumo

7. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-621.Texto completo  Resumo

8. Langabeer JR 2nd, Champagne-Langabeer T, Fowler R, et al. Gender-based outcome differences for emergency department presentation of non-STEMI acute coronary syndrome. Am J Emerg Med. 2019 Feb;37(2):179-82. Resumo

9. Neumann JT, Goßling A, Sörensen NA, et al. Temporal trends in incidence and outcome of acute coronary syndrome. Clin Res Cardiol. 2020 Sep;109(9):1186-92. Resumo

10. National Institute for Cardiovascular Outcomes Research. Interactive reports: clinical sub-specialty reports. 2024 [internet publication].Texto completo

11. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000 Dec;36(7):2056-63.Texto completo  Resumo

12. McManus DD, Gore J, Yarzebski J, et al. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med. 2011 Jan;124(1):40-7.Texto completo  Resumo

13. Roger VL, Weston SA, Gerber Y, et al. Trends in incidence, severity, and outcome of hospitalized myocardial infarction. Circulation. 2010 Feb 23;121(7):863-9.Texto completo  Resumo

14. Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008 Dec;156(6):1026-34. Resumo

15. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69.Texto completo  Resumo

16. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995 Jun 1;91(11):2844-50.Texto completo  Resumo

17. Moreno PR, Falk E, Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994 Aug;90(2):775-8. Resumo

18. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. J Intern Med. 2015 Nov;278(5):483-93.Texto completo  Resumo

19. Centers for Disease Control and Prevention. Smoking and tobacco use​: cigarette smoking. Sep 2024 [internet publication].Texto completo

20. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-49.Texto completo  Resumo

21. Writing Group Members, Mozaffarian D, Benjamin EJ, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-360.Texto completo

22. Gallucci G, Tartarone A, Lerose R, et al. Cardiovascular risk of smoking and benefits of smoking cessation. J Thorac Dis. 2020 Jul;12(7):3866-76.Texto completo  Resumo

23. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005 May 24;111(20):2684-98.Texto completo  Resumo

24. Willett J, Achenbach S, Pinto FJ, et al. The tobacco endgame-eradicating a worsening epidemic: a joint opinion from the American Heart Association, World Heart Federation, American College of Cardiology, and the European Society of Cardiology. Circulation. 2021 Jul 6;144(1):e1-5.Texto completo

25. Willett J, Achenbach S, Pinto FJ, et al. The tobacco endgame: eradicating a worsening epidemic a joint opinion from the American Heart Association, World Heart Federation, American College of Cardiology, and the European Society of Cardiology. J Am Coll Cardiol. 2021 Jul 6;78(1):77-81.Texto completo  Resumo

26. Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936.Texto completo  Resumo

27. Song C, Fu R, Dou K, et al. Association between smoking and in-hospital mortality in patients with acute myocardial infarction: results from a prospective, multicentre, observational study in China. BMJ Open. 2019 Aug 30;9(8):e030252.Texto completo  Resumo

28. Wong ND, Cupples LA, Ostfeld AM, et al. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol. 1989 Sep;130(3):469-80. Resumo

29. Connolly DC, Elveback LR, Oxman HA. Coronary heart disease in residents of Rochester, Minnesota, 1950-1975. III. Effect of hypertension and its treatment on survival of patients with coronary artery disease. Mayo Clin Proc. 1983 Apr;58(4):249-54. Resumo

30. Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.Texto completo  Resumo

31. American Diabetes Association Professional Practice Committee. Introduction and methodology: standards of care in diabetes-2024. Diabetes Care. 2024 Jan 1;47(supplement_1):S1-4.Texto completo

32. Organisation for Economic Co-operation and Development. Overweight or obese population. 2024 [internet publication]​.Texto completo

33. Vasan RS, Pencina MJ, Cobain M, et al. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med. 2005 Oct 4;143(7):473-80. Resumo

34. Freitas Lima LC, Braga VA, do Socorro de França Silva M, et al. Adipokines, diabetes and atherosclerosis: an inflammatory association. Front Physiol. 2015 Nov 3;6:304.Texto completo  Resumo

35. Messerli FH, Sundgaard-Riise K, Reisin ED, et al. Dimorphic cardiac adaptation to obesity and arterial hypertension. Ann Intern Med. 1983 Dec;99(6):757-61. Resumo

36. Rayner JJ, Banerjee R, Holloway CJ, et al. The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity. Int J Obes (Lond). 2018 Mar;42(3):441-7.Texto completo  Resumo

37. Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, et al. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020 Nov 22;19(1):195.Texto completo  Resumo

38. Moussa O, Ardissino M, Heaton T, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J. 2020 Jul 21;41(28):2660-7.Texto completo  Resumo

39. Franklin BA, Thompson PD, Al-Zaiti SS, et al. Exercise-related acute cardiovascular events and potential deleterious adaptations following long-term exercise training: placing the risks Into perspective-an update: a scientific statement from the American Heart Association. Circulation. 2020 Mar 31;141(13):e705-36.Texto completo  Resumo

40. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007 Aug;39(8):1423-34.Texto completo  Resumo

41. Pinckard K, Baskin KK, Stanford KI. Effects of exercise to improve cardiovascular health. Front Cardiovasc Med. 2019 Jun 4;6:69.Texto completo  Resumo

42. Nystoriak MA, Bhatnagar A. Cardiovascular effects and benefits of exercise. Front Cardiovasc Med. 2018 Sep 28;5:135.Texto completo  Resumo

43. Bakker EA, Lee DC, Hopman MTE, et al. Dose-response association between moderate to vigorous physical activity and incident morbidity and mortality for individuals with a different cardiovascular health status: a cohort study among 142,493 adults from the Netherlands. PLoS Med. 2021 Dec;18(12):e1003845.Texto completo  Resumo

44. Kang DS, Sung JH, Kim D, et al. Association between exercise habit changes and mortality following a cardiovascular event. Heart. 2022 Nov 24;108(24):1945-51.Texto completo  Resumo

45. Balling M, Afzal S, Davey Smith G, et al. Elevated LDL triglycerides and atherosclerotic risk. J Am Coll Cardiol. 2023 Jan 17;81(2):136-52.Texto completo  Resumo

46. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016 Sep 27;316(12):1289-97. Resumo

47. El Khoudary ( سمر رياض الخضري ) SR, Chen (陈曦润) X, Nasr ( ألكسس نصر ) AN, et al. HDL (high-density lipoprotein) subclasses, lipid content, and function trajectories across the menopause transition: SWAN-HDL Study. Arterioscler Thromb Vasc Biol. 2021 Feb;41(2):951-61.Texto completo  Resumo

48. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61.Texto completo  Resumo

49. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387-97.Texto completo  Resumo

50. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014 Jun 24;129(25 suppl 2):S1-45.Texto completo

51. Schubert J, Lindahl B, Melhus H, et al. Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J. 2021 Jan 20;42(3):243-52.Texto completo  Resumo

52. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation. 2010 Jan 26;121(3):357-65.Texto completo  Resumo

53. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305.Texto completo  Resumo

54. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999 Feb 24;281(8):727-35.Texto completo  Resumo

55. Eisen A, Bhatt DL, Steg PG, et al. Angina and future cardiovascular events in stable patients with coronary artery disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc. 2016 Sep 28;5(10):e004080.Texto completo  Resumo

56. Vikulova DN, Grubisic M, Zhao Y, et al. Premature atherosclerotic cardiovascular disease: trends in incidence, risk factors, and sex-related differences, 2000 to 2016. J Am Heart Assoc. 2019 Jul 16;8(14):e012178.Texto completo  Resumo

57. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert consensus statement on the state of genetic testing for cardiac diseases. Europace. 2022 Sep 1;24(8):1307-67.Texto completo

58. Montalescot G, Sechtem U, Achenbach S, et al; Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013 Oct;34(38):2949-3003.Texto completo  Resumo

59. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. Dec 2023 [internet publication].Texto completo

60. Qureshi AI, Suri MF, Guterman LR, et al. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. Circulation. 2001 Jan 30;103(4):502-6.Texto completo  Resumo

61. Havakuk O, Rezkalla SH, Kloner RA. The cardiovascular effects of cocaine. J Am Coll Cardiol. 2017 Jul 4;70(1):101-13.Texto completo  Resumo

62. Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17;364(9438):953-62. Resumo

63. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014 Mar 25;129(12):1350-69.Texto completo  Resumo

64. Wang X, Ouyang Y, Wang Z, et al. Obstructive sleep apnea and risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013 Nov 5;169(3):207-14.Texto completo  Resumo

65. Yang SH, Xing YS, Wang ZX, et al. Association of obstructive sleep apnea with the risk of repeat adverse cardiovascular events in patients with newly diagnosed acute coronary syndrome: a systematic review and meta-analysis. Ear Nose Throat J. 2021 May;100(4):260-70.Texto completo  Resumo

66. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-67.Texto completo  Resumo

67. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001 May 16;285(19):2481-5.Texto completo  Resumo

68. Hooning MJ, Aleman BM, van Rosmalen AJ, et al. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1081-91. Resumo

69. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004 Jun 29;109(25):3122-31.Texto completo  Resumo

70. Kalkman DN, Couturier EGM, El Bouziani A, et al. Migraine and cardiovascular disease: what cardiologists should know. Eur Heart J. 2023 Aug 7;44(30):2815-28.Texto completo  Resumo

71. O'Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and reproductive risk factors for cardiovascular disease in women. Circ Res. 2022 Feb 18;130(4):652-72.Texto completo  Resumo

72. Sheidu MO, Agarwala A, Lakshmanan S, et al. Management of pregnancy-related disorders to prevent future risk of coronary artery disease. Heart. 2024 Dec 23;111(2):83-92.Texto completo

73. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-646.Texto completo  Resumo

74. Kris-Etherton PM, Petersen KS, Després JP, et al. Strategies for promotion of a healthy lifestyle in clinical settings: pillars of ideal cardiovascular health: a science advisory from the American Heart Association. Circulation. 2021 Dec 14;144(24):e495-514.Texto completo  Resumo

75. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-37.Texto completo  Resumo

76. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2022 Aug 23;328(8):746-53.Texto completo  Resumo

77. US Preventive Services Task Force; Davidson KW, Barry MJ, Mangione CM, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022 Apr 26;327(16):1577-84.Texto completo  Resumo

78. National Institute for Health and Care Excellence. Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis. Nov 2016 [internet publication].Texto completo

79. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Nov 30;78(22):e187-285.Texto completo  Resumo

80. Gokhroo RK, Ranwa BL, Kishor K, et al. Sweating: a specific predictor of ST-segment elevation myocardial infarction among the symptoms of acute coronary syndrome: Sweating In Myocardial Infarction (SWIMI) study group. Clin Cardiol. 2016 Feb;39(2):90-5.Texto completo  Resumo

81. National Institute for Health and Care Excellence. Acute coronary syndromes​. Nov 2020 [internet publication].Texto completo

82. National Institute for Health and Care Excellence. Acute coronary syndromes in adults. Nov 2020 [internet publication].Texto completo

83. Writing Committee, Kontos MC, de Lemos JA, et al. 2022 ACC Expert consensus decision pathway on the evaluation and disposition of acute chest pain in the emergency department: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Nov 15;80(20):1925-60.Texto completo  Resumo

84. Holmvang L, Clemmensen P, Lindahl B, et al. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol. 2003 Mar 19;41(6):905-15. Resumo

85. Kaul P, Fu Y, Chang WC, et al; PARAGON-A and GUSTO IIb Investigators, Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. J Am Coll Cardiol. 2001 Jul;38(1):64-71. Resumo

86. Vafaie M, Slagman A, Möckel M, et al. Prognostic value of undetectable hs troponin T in suspected acute coronary syndrome. Am J Med. 2016 Mar;129(3):274-82. Resumo

87. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007 Oct;28(20):2525-38.Texto completo  Resumo

88. Roos A, Bandstein N, Lundbäck M, et al. Stable high-sensitivity cardiac troponin T levels and outcomes in patients with chest pain. J Am Coll Cardiol. 2017 Oct 31;70(18):2226-36.Texto completo  Resumo

89. Fresco C, Maggioni FC, Signorini S, et al. Variations in lipopoprotein levels after myocardial infarction and unstable angina: the LATIN trial. Ital Heart J. 2002 Oct;3(10):587-92. Resumo

90. Edvardsen T, Asch FM, Davidson B, et al. Non-invasive imaging in coronary syndromes: recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Eur Heart J Cardiovasc Imaging. 2022 Jan 24;23(2):e6-33.Texto completo

91. Steeds RP, Garbi M, Cardim N, et al. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017 Nov 1;18(11):1191-204.Texto completo  Resumo

92. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-64.Texto completo  Resumo

93. Loutfi M, Ashour S, El-Sharkawy E, et al. Identification of high-risk patients with non-ST segment elevation myocardial infarction using strain doppler echocardiography: correlation with cardiac magnetic resonance imaging. Clin Med Insights Cardiol. 2016 May 10;10:51-9.Texto completo  Resumo

94. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e18-114.Texto completo  Resumo

95. Puelacher C, Gugala M, Adamson PD, et al. Incidence and outcomes of unstable angina compared with non-ST-elevation myocardial infarction. Heart. 2019 Sep;105(18):1423-31. Resumo

96. Hendel RC, Patel MR, Kramer CM, et al. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol. 2006 Oct 3;48(7):1475-97.Texto completo  Resumo

97. Williams MC, Hunter A, Shah AS, et al. Use of coronary computed tomographic angiography to guide management of patients with coronary disease. J Am Coll Cardiol. 2016 Apr 19;67(15):1759-68.Texto completo  Resumo

98. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Resumo

99. Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria for vasospastic angina. Eur Heart J. 2017 Sep 1;38(33):2565-8.Texto completo  Resumo

100. Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987 Jan;1(1):3-14. Resumo

101. Campeau L. Letter: Grading of angina pectoris. Circulation. 1976 Sep;54(3):522-3. Resumo

102. US Preventive Services Task Force. Final recommendation statement. Cardiovascular disease risk: screening with electrocardiography. Jun 2018 [internet publication].Texto completo

103. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-77.Texto completo  Resumo

104. Sandau KE, Funk M, Auerbach A, et al. Update to practice standards for electrocardiographic monitoring in hospital settings: a scientific statement from the American Heart Association. Circulation. 2017 Nov 7;136(19):e273-344.Texto completo  Resumo

105. Damluji AA, Forman DE, Wang TY, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart Association. Circulation. 2023 Jan 17;147(3):e32-62.Texto completo  Resumo

106. Thadani U, Opie LH. Nitrates for unstable angina. Cardiovasc Drugs Ther. 1994 Oct;8(5):719-26. Resumo

107. Gibler WB, Cannon CP, Blomkalns AL, et al. Practical implementation of the guidelines for unstable angina/non-ST-segment elevation myocardial infarction in the emergency department: a scientific statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Acute Cardiac Care), Council on Cardiovascular Nursing, and Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Society of Chest Pain Centers. Circulation. 2005 May 24;111(20):2699-710.Texto completo  Resumo

108. Bavishi C, Panwar S, Messerli FH, et al. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015 Sep 1;116(5):809-17. Resumo

109. Navarese EP, Khan SU, Kołodziejczak M, et al. Comparative efficacy and safety of oral P2Y(12) inhibitors in acute coronary syndrome: network meta-analysis of 52 816 patients from 12 randomized trials. Circulation. 2020 Jul 14;142(2):150-60.Texto completo  Resumo

110. Ruiz-Nodar JM, Esteve-Pastor MA, Rivera-Caravaca JM, et al. One-year efficacy and safety of prasugrel and ticagrelor in patients with acute coronary syndromes: results from a prospective and multicentre ACHILLES registry. Br J Clin Pharmacol. 2020 Jun;86(6):1052-61.Texto completo  Resumo

111. Turgeon RD, Koshman SL, Youngson E, et al. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020 Mar 1;180(3):420-8.Texto completo  Resumo

112. Coughlan JJ, Aytekin A, Lahu S, et al. Ticagrelor or prasugrel for patients with acute coronary syndrome treated with percutaneous coronary intervention: a prespecified subgroup analysis of a randomized clinical trial. JAMA Cardiol. 2021 Oct 1;6(10):1121-9.Texto completo  Resumo

113. O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Jan 29;61(4):e78-140.Texto completo  Resumo

114. Goodwin MM, Desilets AR, Willett KC. Thienopyridines in acute coronary syndrome. Ann Pharmacother. 2011 Feb;45(2):207-17. Resumo

115. Menichelli M, Neumann FJ, Ndrepepa G, et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes: results from a randomized trial. Ann Intern Med. 2020 Sep 15;173(6):436-44. Resumo

116. Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 4;368(14):1303-13.Texto completo  Resumo

117. Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14;382(9909):1981-92. Resumo

118. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165.Texto completo  Resumo

119. Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002 May 1;39(9):1456-63. Resumo

120. Eikelboom JW, Anand SS, Malmberg K, et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000 Jun 3;355(9219):1936-42. Resumo

121. Andrade-Castellanos CA, Colunga-Lozano LE, Delgado-Figueroa N, et al. Heparin versus placebo for non-ST elevation acute coronary syndromes. Cochrane Database Syst Rev. 2014 Jun 27;(6):CD003462.Texto completo  Resumo

122. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006 Apr 6;354(14):1464-76.Texto completo  Resumo

123. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006 Apr 5;295(13):1519-30. Resumo

124. Navarese EP, Andreotti F, Kołodziejczak M, et al. Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients. Thromb Haemost. 2015 Nov;114(5):933-44. Resumo

125. Gibson RS, Hansen JF, Messerli F, et al. Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies. Am J Cardiol. 2000 Aug 1;86(3):275-9. Resumo

126. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet. 2000 May 20;355(9217):1751-6. Resumo

127. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995 Sep 1;92(5):1326-31.Texto completo  Resumo

128. Yusuf S, Sleight P, Pogue J, et al; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Texto completo  Resumo

129. Brito V, Ciapponi A, Kwong J. Factor Xa inhibitors for acute coronary syndromes. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD007038. Resumo

130. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Texto completo  Resumo

131. Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. Eur Heart J. 2020 Nov 21;41(44):4245-55.Texto completo  Resumo

132. Oyama K, Giugliano RP, Tang M, et al. Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J. 2021 Dec 14;42(47):4821-9.Texto completo  Resumo

133. Brown TM, Pack QR, Aberegg E, et al. Core components of cardiac rehabilitation programs: 2024 update: a scientific statement from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2024 Oct 29;150(18):e328-47.Texto completo  Resumo

134. Povsic TJ, Vavalle JP, Alexander JH, et al. Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. EuroIntervention. 2014 Aug;10(4):431-8.Texto completo  Resumo

135. Povsic TJ, Wargin WA, Alexander JH, et al. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. Eur Heart J. 2011 Oct;32(19):2412-9. Resumo

136. Staudacher DL, Putz V, Heger L, et al. Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2019 Sep;8(6):520-6. Resumo

137. De Caterina R, Prisco D, Eikelboom JW. Factor XI inhibitors: cardiovascular perspectives. Eur Heart J. 2023 Jan 21;44(4):280-92.Texto completo  Resumo

138. DiNicolantonio JJ, Lavie CJ, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clin Proc. 2013 Jun;88(6):544-51.Texto completo  Resumo

139. Fisher SA, Zhang H, Doree C, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015 Sep 30;2015(9):CD006536.Texto completo  Resumo

140. Choudry F, Hamshere S, Saunders N, et al. A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial†. Eur Heart J. 2016 Jan 14;37(3):256-63.Texto completo  Resumo

141. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019 Dec 26;381(26):2497-505.Texto completo  Resumo

142. Chen Y, Zhang H, Chen Y, et al. Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials. Clin Rheumatol. 2022 Jun;41(6):1873-87. Resumo

143. Razavi E, Ramezani A, Kazemi A, et al. Effect of treatment with colchicine after acute coronary syndrome on major cardiovascular events: a systematic review and meta-analysis of clinical trials. Cardiovasc Ther. 2022 Apr 13;2022:8317011.Texto completo  Resumo

144. Bouabdallaoui N, Tardif JC, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020 Nov 7;41(42):4092-9.Texto completo  Resumo

145. Pettersen JA, Singh A. Potentially reversible rapid-onset weakness: recognizing colchicine Toxicity. Am J Med. 2018 Feb;131(2):e59-60.

146. Schwartz GG, Leiter LA, Ballantyne CM, et al. Dalcetrapib reduces risk of new-onset diabetes in patients with coronary heart disease. Diabetes Care. 2020 May;43(5):1077-84.Texto completo  Resumo

147. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med. 2022 Sep 15;387(11):967-77.Texto completo  Resumo

148. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-32.Texto completo  Resumo

149. Wise J. Semaglutide reduces risk of major cardiovascular events by 20%, finds study. BMJ. 2023 Nov 13;383:2668.

150. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 5;366(1):20-33.Texto completo  Resumo

151. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004 Jun 9;291(22):2727-33.Texto completo  Resumo

152. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999 Feb 24;281(8):707-13.Texto completo  Resumo

153. Chang WC, Boersma E, Granger CB, et al. Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. Am Heart J. 2004 Jul;148(1):62-71. Resumo

154. Sheridan PJ, Crossman DC. Critical review of unstable angina and non-ST elevation myocardial infarction. Postgrad Med J. 2002 Dec;78(926):717-26. Resumo

155. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000 Aug 16;284(7):835-42.Texto completo  Resumo

156. Boersma E, Pieper KS, Steyerberg EW, et al; The PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. Circulation. 2000 Jun 6;101(22):2557-67.Texto completo  Resumo

157. Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003 Oct 27;163(19):2345-53.Texto completo  Resumo

158. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2005 Sep 6;46(5):906-19. Resumo

159. Jha MK, Qamar A, Vaduganathan M, et al. Screening and management of depression in patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2019 Apr 16;73(14):1827-45.Texto completo  Resumo

160. Frost JL, Rich RL Jr, Robbins CW, et al. Depression following acute coronary syndrome events: screening and treatment guidelines from the AAFP. Am Fam Physician. 2019 Jun 15;99(12):Online.

161. Abdullah A, Radivojevic A, Abu Jad AA, et al. Achieving the balance-a systematic review on treating depression post myocardial infarction​.Cardiol Res Cardiovasc Med. 14 Oct 2022:177.Texto completo

162. Yandrapalli S, Malik A, Pemmasani G, et al. Sex differences in heart failure hospitalisation risk following acute myocardial infarction. Heart. 2021 Oct;107(20):1657-63. Resumo

163. Rinde LB, Lind C, Småbrekke B, et al. Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost. 2016 Jun;14(6):1183-91.Texto completo  Resumo

164. Schechtman KB, Capone RJ, Kleiger RE, et al. Risk stratification of patients with non-Q wave myocardial infarction: the critical role of ST segment depression - the Diltiazem Reinfarction Study Research Group. Circulation. 1989 Nov;80(5):1148-58. Resumo

165. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.Texto completo

166. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo  Resumo

167. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018 Oct;15(10):e190-252.Texto completo  Resumo

168. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995 Feb 15;91(4):999-1005.Texto completo  Resumo

169. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008 Oct 21;118(17):1768-75.Texto completo  Resumo

170. Wenger NK, Froelicher ES, Smith LK, et al. Cardiac rehabilitation as secondary prevention. Agency for Health Care Policy and Research and National Heart, Lung, and Blood Institute. Clin Pract Guidel Quick Ref Guide Clin. 1995 Oct;(17):1-23. Resumo

171. DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994 May 1;120(9):721-9. Resumo

172. Witt BJ, Jacobsen SJ, Weston SA, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol. 2004 Sep 1;44(5):988-96. Resumo

173. Scottish Intercollegiate Guidelines Network. Cardiac rehabilitation: a national clinical guideline. Jul 2017 [internet publication].Texto completo

174. Beleigoli A, Foote J, Gebremichael LG, et al. Clinical effectiveness and utilisation of cardiac rehabilitation after hospital discharge: data linkage analysis of 84,064 eligible discharged patients (2016-2021). Heart Lung Circ. 2024 Jul;33(7):1036-45.Texto completo  Resumo